Expression of NKD1 and its clinical significance in acute myeloid leukemia
HAN Li1, YAO Dong-ming2, ZHOU Jing-dong3, XIAO Gao-fei1, LIN Jiang1, GUO Hong1, QIAN Jun3
(1. Department of Central Laboratory, 2. Department of Clinical Laboratory, 3. Department of Hematology, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002, China)
Abstract：Objective： To investigate the expression of NKD1 in patients with acute myeloid leukemia(AML) and analyze its clinical significance. Methods： Realtime quantitative PCR was performed to detect NKD1 mRNA level in the bone marrow mononuclear cells from 125 de novo AML patients and 22 controls. Clinical significance of NKD1 expression was analyzed by comparing the clinical parameters in the two groups. Results： NKD1 expression in AML patients was significantly lower than controls(U=805, P=0.002). There were no significant differences in sex, age, blood parameters, bone marrow cell percentages, platelets counting, FAB/WHO subtypes and ten genes mutations between the patients with highexpression and lowexpression NKD1(both P>0.05). However, NKD1 highexpressed patients were showed to have higher levels of hemoglobin than lowexpression patients(U=1 339, P=0.029). After the induction therapy on the patients, there was no significant difference in complete remission rate between the two group patients (P>0.05). However, the lowexpression NKD1 group had shorter survival time than the group with highexpression NKD1 group in all AML, nonM3 AML and cytogenetically normal AML patients(both P<0.05). Conclusion： AML patients showed lowexpression NKD1, which could be used as a molecular marker for predicting prognosis in de novo AML patients.
［Key words］NKD1; acute myeloid leukemia; expression; prognosis
2016, Vol. 26 
